WeTrials
Recruiting

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

What is this study?

This study is testing a new experimental drug called MDNA11, both by itself and combined with an immunotherapy drug called pembrolizumab, to see how well they help the immune system fight advanced solid tumors. Researchers want to find the safest and most effective dose to help patients with various types of hard-to-treat cancers.

Who can participate?

Adults aged 18 and older with confirmed advanced or spread-out solid tumors may be able to join. Participants need to be generally active, have well-functioning vital organs like the liver and kidneys, and be willing to follow all study rules.

What will happen?

Participants will receive the study treatment, which involves the experimental drug MDNA11 alone or alongside a standard immunotherapy drug. The medical team will closely monitor your health, check for side effects, and see how your body responds to the treatment.

Where and when?

This study is currently recruiting participants at multiple locations in California, United States. Your care team will guide you on visit schedules and specific locations.

Key Points
  • 1Tests a new immune-boosting drug called MDNA11.
  • 2Open to adults with various types of advanced solid tumors.
  • 3Currently recruiting patients at study sites in California.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell CarcinomaTriple Negative Breast CancerNon-Small Cell Lung Cancer SquamousNon-Small Cell Lung Cancer Non-squamousColorectal Cancer (MSI-H)Gastric CancerCervical CancerBasal Cell CarcinomaBladder CancerMerkel Cell CarcinomaSquamous Cell Carcinoma of Head and NeckCutaneous Squamous Cell CarcinomaPleural MesotheliomaEsophageal CancerEndometrial CarcinomaSolid TumorSolid Tumor, AdultMSI-H Solid Malignant TumorCancer With A High Tumor Mutational BurdenEpithelial Ovarian CarcinomaPrimary Peritoneal CancerGastroesophageal Junction (GEJ) CancerAcral MelanomaMucosal MelanomaCutaneous MelanomaDMMR Solid Malignant TumorFallopian Tube CancerOvarian CancerMSI-H CancerDMMR CancerPancreas Adenocarcinoma (MSI-H)Skin CancerViral CancerCervical CancersEndometrial Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.